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Abstract 
 
Control Physicochemical Properties of Nanoparticle Surfaces to Modulate Immune-cell 
Recruitment to Scaffolds 
Stephen Bady 
 
 
Although many complex tissue engineering scaffolds have been developed, the number of 
translated treatments remains stagnant. Successful applications of scaffolds in regenerative 
medicine often requires scaffolds to elicit minimal host immune response and controlled release 
of bioactive molecules. Nanoparticles have shown great promise in the controlled release of 
therapeutics to aid tissue engineering. However, nanoparticles incorporated in tissue engineering 
scaffolds causes extra inflammatory responses. Although the release of anti-inflammatory drugs 
has been shown to reduce the foreign body response to scaffolds in vivo, the drugs also interfere 
with immune cells that are vital for tissue regeneration. Proposed here is a nanoparticle embedded 
scaffold drug delivery system designed to minimize the host immune response by controlling the 
physiochemical properties of nanoparticles. This system embeds PLGA nanoparticles with or 
without encapsulated immunosuppressant drugs in the walls of alginate scaffolds. The effects of 
surface modification and release of dexamethasone on immune cell recruitment to scaffolds in 
vivo were explored. Red Blood Cell Membrane (RBCM) coating on PLGA nanoparticles showed 
a decrease in neutrophil recruitment as well as an increased number of CD4+ T cells in the 
scaffolds, which are important for tissue regeneration. Our approach is a new strategy in 
minimizing the induced foreign body inflammatory response of nanoparticles used for tissue 
regeneration.   
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1. Introduction 
1.1 Tissue Engineering  
Tissue engineering has been a promising avenue for the repair or replacement of 
malfunctioning or absent human tissues. The aim of tissue engineering is to provide treatment 
for tissues or organs in place of conventional or ineffective pharmaceutical treatments. [1]This 
approach utilizes cells of various sources, matrixes for cell growth, and bioactive molecules 
for system control. Recently the approaches to optimize the basic concept of tissue engineering 
has increased in number and complexity. [2]Scaffolds have played a large role in tissue 
engineering, providing a matrix for cell growth and function. These approaches aim to control 
the cell-to-scaffold interaction, immune reaction, and possible delivery of bioactive factor. 
Despite this increase, the number of translational therapies has remained stagnant and the 
number of commercial investments in the field has decreased by 90%. [3] The modification of 
scaffolds must be coupled with appropriate materials research.  The use of nanoparticles in 
tissue engineering scaffolds and their innate effect was investigated as a possible strategy to 
reduce the scaffold induced foreign body response, which can have adverse effects on 
treatment.  
 
Before nanoparticles are discussed it is important to review the general tissue engineering 
approach taking a closer look at the three-component system of cell, scaffold, and bioactive 
molecules. Next it is appropriate to discuss the various approaches of tissue engineering and 
give specific examples of applications ranging from the treatment of tissues severely damaged 
by cancer, congenital anomalies, or side effects from other treatments. An overview of drug 
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delivery will be given. Followed by a study of the addition of nanoparticles to the system and 
the importance of investigating their effect on the system-induced immune response.  
 
1.1.1 Cells 
To restate, the process of tissue engineering uses source cells and provides the necessary 
environment (scaffold and bioactive molecule) for growth allowing normal cell function and 
eventual treatment. These cells can be sourced from patient’s (autologous), other humans 
(allogeneic), or from animals (xenogeneic). [4] The cell source is of vital importance to the 
effectiveness of the treatment. The difference is due to the immune response of the patient. 
Autologous cells, sourced from the patient, have the lowest probability of causing an adverse 
immune response, while allogeneic and xenogeneic cells will require an immunosuppressant 
therapy upon tissue insertion, otherwise the body will mount an attack on these foreign cells.  
 
The discussed approach is harvest cells from patients or donors, culture them with a scaffold, 
and transfer them back into patients. Although autologous cells seem the appropriate route, it 
is not always practical to harvest enough cells from the patient. For instance, it may be very 
difficult to harvest enough cardiac cells from a patient suffering from myocardial infarction. 
This task becomes more difficult when a patient is extremely diseased (healthy cells are hard 
to come by) or is elderly. Cell culturing becomes necessary at this point but requires additional 
steps and facilities, introducing the possibility of contamination, which may also have an 
adverse effect on treatment.  
 
This gives rise to the harvesting of allogenic cells from healthy patients. These cells have 
shown promise in topical application for burn victims.  [5] Allogenic cells have been shown to 
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be effective wound covers, due to their release of growth factor compared to non-biological 
covers. [6] Using cells sourced from the body, which induce minimum immune response, 
usually contain components not present in synthetic materials (i.e. growth factor). However, 
xenogeneic cells show a high epidermal growth activity but also a high risk of viral infection.  
 
Cells can also be categorized based on their extent of differentiation. Embryonic stem and germ 
cells are non-differentiated cells meaning they can differentiate into all manner of cells. These 
pluripotent cells are promising in the field of tissue engineering due to their potential to 
increase their number but come with ethical issues. If embryonic stems are harvested from a 
fertilized egg they are technically allogenic cells to a patient and adverse response is possible 
due to gene mismatch. This issue may be overcome by somatic cell nuclear transfer, which 
allows for a somatic cell to generate autologous totipotent stem cells, but this ethical dilemma 
also comes with the risk of clonal human reproduction. [7]  
 
To circumvent this, adult (somatic) stem cells, which can differentiate into multiple cell 
lineages (under the proper conditions) have been heavily studied. Mainly hematopoietic stem 
cells and mesenchymal stem cells have been studied, being able to differentiate into 
eosinophils, erythrocytes, megakaryocytes, osteoclasts and B and T cells; and osteocytes, 
chondrocytes, adipocytes, tenocytes, myocytes and bone marrow stromal cells respectively. 
[8] Progenitor cells are limited to defined lineage but can provide organ-specific cell types. 
Combined with growth factor and cytokine(s) that promote differentiation these cells can be 
used for tissue regeneration, if carried or delivered in an appropriate scaffold. While the 
induced immune response from the cell component has been thoroughly studied and reduced 
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to increase treatment efficiency, the scaffold component, which carries or recruits these cells 
may cause unnecessary inflammation.  
 
1.1.2 Scaffolds  
The main function of scaffolds or artificial extracellular matrix (ECM), in tissue engineering 
is to provide a frame for cells to proliferate, differentiate, and undergo biosynthesis. This 
function requires adequate design, appropriate material selection, and degradation kinetics, 
including byproducts. Scaffolds must be synthesized with the right pore size for cell seeding 
or infiltration, migration, nutrient supply, and waste removal of cells. Materials that are 
biocompatible and match the mechanical properties of the simulated environment must be 
selected. Also, the materials selected must have well defined degradation or absorption kinetics 
with nontoxic or noncytotoxic byproducts.  
 
Pore size to network ratio as well as surface area to mechanical properties are connected in 
various ways and all must be considered when designing a tissue engineering scaffold. 
Depending on the function of the scaffold the optimal pore size range will change. For instance, 
it was found through a study of different pore sizes corresponding to different specific surface 
areas that the optimal pore size for cell attachment and viability in collagen-glycosaminoglycan 
(CG) scaffolds was 95.9-150.5 μm. [9] This study was done using four different pore sizes 
manufactured through lyophilization. MC3T3-E1 mouse clonal osteogenic cells were seeded 
on the different pore size scaffolds. Interestingly, there was non-statistical differences in 
attachment after 2 days but there was a relationship between the number of active cells that 
attached and pore size. However, this pore size range cannot be used for all cases and a more 
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general rule of 100 to 500 μm pore size range is used, until proper system study is made. 
Meaning pore size can and should be optimized for application.  
 
Pore size alone does not ensure cell activity however. Pores must also form an interconnected 
network that allows for the transfer of nutrients and waste to sustain cell function. The 
increased network porosity will decrease the mechanical properties of your scaffold, which are 
of vital importance.  It has been well documented that stem cells can be aided in differentiation 
by mechanical stimuli provided by ECM. This includes ECM structure, elasticity, and 
composition. [10] It has also been shown that the scaffold composition can play a role in cell 
activity, including differentiation. [11] In this study, the differentiation of chondrogenic human 
adipose-derived adult stem cells were investigated in alginate and agarose hydrogels and 
porous gelatin scaffolds. Cells in different scaffold compositions took on different shapes, even 
with the same moduli per scaffold condition.  In a different study, it was shown that cell 
proliferation and growth can affect the mechanical properties of scaffolds, which considering 
the effect of mechanical stimuli could cause alternative differentiation of proliferated stem 
cells. [12]  
 
The design alone does not determine if the scaffold will be successful in its application, as it 
has been shown that composition plays a large role in cell interaction, scaffold material 
selection is also extremely important. Material selection should be determined by 
biocompatibility, tissue-scaffold affinity, and degradation kinetics mainly. Many 
biocompatible materials have been used to form scaffolds by various synthesis routes. Poly(α-
hydroxyacid)’s, including polyglycolide (PGA), Poly lactide-glycolide acid (PLGA), and 
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poly(L-lactide) acid PLLA have been studied widely. [13] Morita et. al studied the degradation 
of PGA and its copolymers and showed that its tensile strength is reduced in half in two weeks. 
A scaffold made of this material would have a significantly different microenvironment due to 
this change in mechanical properties and may be unable to support cell growth and function in 
a short period of time. PGA and copolymer PLGA are thus unsuitable as scaffolding material 
for many applications but due to this degradation, encapsulation and release from particles 
made of these materials are of interest. On the other end of the spectrum is PLLA, which can 
take between 3-6 years to degrade and resorb. This extended presence could potentially disrupt 
normal cell function and impede tissues that may have grown within the scaffold. It is 
important to note that the biocompatible by products allow for cells to continue normal 
function absent of a harmful immune response.  
 
Degradation kinetics can be tuned to an extent by changing the molecular weight of the 
synthetic polymer, but a more effective approach is to use a polymer which degrades in a 
controlled fashion. While the synthetic polymers described above degrade through non-
enzymatic hydrolysis natural biomaterials such as hyaluronic acid and collagen degrade by 
enzymatic hydrolysis. These naturally occurring polymers usually have lower mechanical 
properties compared to Poly(α-hydroxyacid)’s but can show better biocompatibility and 
degradation kinetics. Most are hydrophilic (barring chitin) and have hydrolysable bonds.  
 
Alginate has been studied as a promising scaffolding material due to its multilevel tunability, 
biocompatibility, and encapsulation applications. The mechanical properties of alginate can be 
controlled by the ratio of (1-4)-linked β-D mannuronate (M) to C-5 epimer α-L guluronate (G) 
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residues. This linear anionic polysaccharide can be made stiffer with consecutive G blocks, 
more pliant with consecutive M blocks, and even highly elastic with an appropriate alternative 
ratio of M to G residues.  Alginate can be ionically crosslinked using Ca2+ ions. This process 
produces a water-insoluble gel but in vivo these Ca2+ ions will be exchanged with Na+, 
effectively reversing the strength of the crosslink and the integrity of the scaffold. [14] Alginate 
can also be crosslinked by adding methacrylate functional group. These MA alginates have 
been shown to have tunable swelling behavior, elastic moduli, and degradation rates by 
controlling the degree of methacrylation. Moreover, they show the ability to encapsulate cells 
and promoted viability as seen from live/dead cell staining and MTS assay of bovine 
chondrocytes. Lastly, gelation by methacrylation forms macro-porous structure. [15] Thus, 
MA alginate is highly biocompatible, has multilevel mechanical tunability, and can promote 
living cells making this material of interest to reduce scaffold induced foreign body immune 
response.  
 
1.2 Bioactive Molecule  
In addition to cells and scaffolds, bioactive molecules play a large role in tissue engineering. 
These molecules are usually encapsulated in the scaffold to promote cell growth or genetically 
modified cells, able to produce desired bioactive molecules, are seeded into cells for their 
production. Bioactive molecules are a general class of molecules and macromolecules that 
influences living organism(s), tissue(s), and/or cell(s). These molecules may be proteins, 
enzymes, vitamins, metals, cytokines, etc.  
 
The ability to influence the differentiation or growth of cells is an advantage to tissue 
engineering approaches. This advantage is based on the ability for tissue engineering scaffolds 
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to delivery growth factor. These growth factors are proteins that are secreted by cells or because 
of cell-cell communication.  In tissue engineering bone morphogenic proteins (BMPs, 
fibroblast growth factor (FGF-2), and transforming growth factor-β (TGF-β) have been heavily 
studied. These bioactive molecules have been shown to improve the formation of new and 
damaged bone in vivo. [16] Using BMP-2 loaded PLGA/Hydroxy Appetite (Hap) composites, 
bone healing was study and the most dominant factor was sustained release of loaded BMP-2 
from scaffolds (electrospinning fiber synthesized). In a different study that utilized a DNA 
(bioactive molecule) and PLGA/HAp composite scaffold for bone tissue engineering it was 
shown that transfection efficiency of DNA is highly improved by sustained chitosan particle 
release from scaffolds. Unfortunately, this is accompanied by an adverse immunological 
reaction which can greatly diminish the treatment efficiency. [17] A negligible immune 
response is required to accommodate the sensitivity of many treatments in tissue engineering, 
especially regarding immunotherapies.  This can be accomplished through materials selection 
and/or immunosuppressant sustained release, this should not distract from the importance of 
sustained release over burst release in many tissue engineering applications. 
 
1.3 Approaches and Applications 
So far, the ability to regrow new tissues or heal damaged tissues has been highlighted as a 
major use of scaffolds in tissue engineering. Tissue engineering scaffolds are also applicable 
in different immunotherapies. In both tissue engineering scaffolds and scaffolds for 
immunotherapy the design, material selection, and bioactive molecules are optimized to get 
the desired immune response.  
 
9 
 
The ability to leverage our immune systems is at the center of immunotherapy. This leveraging 
may be obtained from either enhancing or suppressing an immune response, either swing must 
be controlled. The former cases are classified as activation immunotherapies, while the latter 
are suppression immunotherapies. The last 20 years has shown an increase in 
immunomodulatory regimes due to advantages including fewer side effects and lower buildup 
of drug resistance. Immunotherapies can be cell based, in the form of cytotoxic T lymphocytes 
(CTL) killing cancer cells or based around interferons, cellular membranes, or chemokines. 
Regardless of the bases of the immunotherapy a firm balance of the immune response is vital. 
The biomaterials used must either have a noninfluential or proactive effect. To investigate the 
effect of different nanoparticles and their overall effect on potential immunotherapies first a 
review of immunotherapy will be given, followed by a description of key immune-
components, and then a discussion of drug delivery.  
 
1.3.1 Immunotherapy 
Immunomodulators are used to influence the immune system, resulting in either activation or 
suppression immunotherapy depending on modulator class. For example, interleukins are a 
special group of cytokines that function as signaling molecules for the immune system. 
Deficiencies in these cytokines decrease the development and differentiation of T and B 
lymphocytes. These deficiencies have been used to describe most autoimmune diseases or 
immune deficiency. Interleukin-2 (IL-2) has been approved by the Food and Drug 
Administration (FDA) for the treatment of cancer. Due to its pivotal roles in immune system 
rejection prevention. IL-2 can help promote differentiation of certain immature T cells into 
regulatory T-cells, which in turn can suppress other T-cells that could otherwise attack normal 
healthy cells. IL-2 is just one of many interleukins used, IL-7 and IL-12 have also seen 
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extensive research. Moreover, there are many immunomodulators at work in many different 
immunotherapies. [18] 
 
1.3.1.1 Activation Immunotherapies  
Activation immunotherapies seek to enhance or ramp up normal immune functions in directed 
manners. These treatments are unique in their mechanism but similar as they all use an 
enhanced number of immune cells. A diverse set of immunotherapies have been adapted as 
cancer treatments.  Granulocyte modulator Colony-Stimulating Factor (GM-CSF) 
Lymphocytes have been shown effective against tumor cells after being augmented with 
appropriate stimulatory cytokines. In this study tumor cells were modified and irradiated to 
produce GM-CSF, which promoted dendritic cells and macrophages to present tumor antigens 
to T-cells. This led to natural killer T-cells targeting cancer cells. [19]  Imiquimod, a topical 
immunotherapy, produces interferons, which stimulates patient’s killer T-cells to abnormality 
(warts, basal cell cancer, etc.). The first approach requires the harvesting, farming, modulating, 
and reinjection of immune cells while the former doesn’t use host cells in the therapy. 
However, both systems introduce possible complications. In the first, there is needless 
inflammation from the multiple injections and the effectiveness of lymphocytes once 
modulated outside of the body comes into question. These issues could be circumvented by 
minimizing injections and modulating host immune cells in vivo. However, this would require 
a stable delivery system of immunomodulator that didn’t in and of itself effect immune 
conditions or modulation. While simultaneously staying in the affected area, recruiting specific 
immune cells, not inciting an adverse immune response, and steadily releasing modulator.  This 
would allow specific immune cells to be stimulated or enhanced at the site needed. 
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Other activation immunotherapies include T-cell adoptive transfer, immune enhancement 
therapy, immune recovery, and vaccination. T-cell adoptive transfer uses extracted T-cells, 
engineering them to be cancer targeting or tumor-infiltrating. Once active, these lymphocytes 
are cultured with IL-2. These T-cells cannot be transferred back into the patient to fight cancer 
cells yet. If they were, regulatory T-cells would compete with the modified T-cells as well as 
other lymphocytes that seek to maintain homeostatic cytokines. Seen as an enemy, before 
reinfusion the patient must be irradiated to achieve lymphodepletion. These reinfused T-cells 
will multiply in vivo and studies have recorded their proliferation for 6-12 months. This is a 
specific form of immune enhancement therapy. In general, this encompasses therapies that use 
a patient’s toxic immune cells (natural killer cells, cytotoxic T lymphocytes, etc.) and multiples 
their numbers in vitro to be later injected/reinfused. Immune recovery is also possible by way 
of cytokines introduced into an immune deficient patient. IL-7 and IL-2 have been studied for 
these purposes in different immunotherapies, some reaching clinical trials. Vaccinations are 
also possible through antimicrobial immunotherapy. This refers to the stimulating of the 
immune system to respond to the specific microbial or infectious agent in manageable doses.     
 
1.3.1.2 Other Immunotherapies 
Suppression immunotherapies seek to reduce an abnormal immune response or to reduce 
normal immune response in cases of a transplant. Immunosuppressive drugs are used to treat 
autoimmune diseases and to manage organ transplantation (preventing rejection).  Many 
immunosuppressive drugs attempt to stop lymphocyte proliferation, these are known as 
cytostatic drugs. While glucocorticoids are immunosuppressant drugs that inhibit lymphocyte 
activation. There are also immunosuppressive antibodies which can provide a quick immune 
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suppression. Generally, the immune system is not completely suppressed, but rather managed 
for a specific purpose. [20] 
 
1.4 Nanoparticles 
The use of nanotechnology in medicine has proved very beneficial in the field of drug delivery. 
Nanoparticles have found this role due to their low toxicology, size, and new ways to deliver 
drugs. [21] Nanoparticle drug delivery systems have been formulated from naturally occurring 
biological membranes (i.e. lipids), various polymers, and even solid metal containing particles. 
These particles have good surface to volume ratios allowing them to bind, absorb, and carry 
other substances/compounds in a functionalized manner. [21] The composition of the 
nanoparticle will greatly affect its interactions with the body. When considering a nanoparticle 
as a drug carrier it is important to control the drug incorporation and release, the ease of 
formulation and stability, and overall drug targeting and effectiveness. These considerations 
can be controlled by choosing the appropriate nanoparticle composition, synthesis, and 
encapsulated drug.  
 
1.4.1 Material – Immune Response 
The key component to the effectiveness of nanoparticles as drug carriers is their size. 
Nanoparticles can penetrate cell membranes, cross the blood brain barrier, bind and stabilize 
proteins, and release encapsulated drug after endocytosis. Their ability to fight cancer as 
chemotherapy carries has already been studied heavily. [22] There are many pitfalls to the use 
of nanoparticles, including poor drug loading, high burst release, aggregation, and toxicity to 
name a few. The use of PLGA, PLGA-PEG, and Red blood cell membrane coated PLGA is 
meant to offset some of these pitfalls.   
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1.4.1.1 PLGA 
Poly, DL, lactic-co-glycolic Acid (PLGA) has been shown to decrease the immune response 
in vivo. In this study PLGA was compared to lipopolysaccharide (LPS) in female Balb/C mice. 
When orally treated with PLGA nanoparticles the expression of pro-inflammatory cytokines 
IL-2, IL-6, IL-12p and TNF-alpha in plasma was found to remain low and model ZnO levels 
(within 24 hours). While LPS, found in the outer membrane of Gram-negative bacteria, elicited 
a strong immune response. This was indicated by the release of pro-inflammatory cytokines as 
well as anti-inflammatory IL-10 and INF-y, while these also remained low in PLGA treated 
mice. [23] These results indicate that PLGA nanoparticles show a low production of cytokines 
and may be used in immunotherapies without inducing an extreme immune response.  
 
1.4.1.2 PLGA-PEG 
PLGA has received so much attention due to its biodegradability and biocompatibility, FDA 
and EMA approval for drug delivery, hydrophobic and hydrophilic drug encapsulation, and 
due to its composition tunability. [24] The copolymerization with PEG allows PLGA-PEG 
nanoparticles to reduce the nonspecific effects of protein adsorption and colloidal grouping. In 
testing the circulation of PLGA NP versus PLGA-PEG NP, it was shown that the PEG 
modified NP could remain in circulation for 5 h with only 30% of NP cleared in that time. 
While 66% of PLGA NP were cleared in 5 minutes. [25] This result indicates that the addition 
of PEG can facilitate the circulation of the lack of immune targeting of PLGA NP. Although 
the exact mechanism of this cloaking is not yet revealed, it is worth studying for improved 
treatments.  
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Figure 1. Schematic of Surface modification of PLGA. Reproduced from Danhier, Fabienne, et al. "PLGA-Based Nanoparticles: An 
Overview of Biomedical Applications."   
 
1.4.1.3 Red Blood Cell Membrane (RBCM) 
Another approach to increase the clearance time of macrophages or to decrease an immune 
response is to modify the surface of nanoparticles with coatings. Red blood cell membrane has 
been shown effective in long circulating cargo delivery. Mice injected with fluorophore-loaded 
nanoparticles displayed better half-life among RBCM coated particles over controls (synthetic 
stealth materials). These results are attributed to biomimetic approaches’ functionalization of 
particles with membrane lipids and associated membrane proteins. [26] 
 
1.4.2 Encapsulation- in scaffolds for drug release 
Nanoparticles size allows them to transverse many barriers in the body allowing for novel drug 
delivery. Their ability to be functionalized for targeted drug delivery is only as important as their 
ability to encapsulate and release said drugs in a controlled fashion. A drug delivery system that 
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has a high encapsulation efficiency (EE) for both hydrophobic and hydrophilic drugs is desired. 
Moreover, the controlled release of these drugs is required. Rapamycin and Dexamethasone are 
both immunosuppressant drugs, which were encapsulated in nanoparticles and packaged in 
scaffolds.  
 
1.4.2.1 Rapamycin  
Rapamycin is an immunosuppressant drug that finds use in transplant rejection prevention and 
cancer treatments, its structure is shown in Figure 2. [27] Its immunosuppressant features are 
usually described by its inhibition of the activation of T-cells and B-cells by reducing production 
of IL-2. Rapamycin is a mTOR inhibitor allowing it to block the signaling of the two protein 
complexes mTORC1 and mTORC2, which regulates the cellular metabolism, growth, and 
proliferation. [28] It has a solubility in water of 0.0026 mg/mL (20C), making it generally 
hydrophobic. [29] This immunosuppressant drug can be encapsulated in a nanoparticle for 
controlled release allowing scaffolding matrices to perform their functions undisturbed by the host 
immune system. [30] 
 
Figure 2.Skeletal formula of Rapamycin ( sirolimus, brand name Rapamune) — an mTOR inhibitor. Recreated from LC 
Laboratories certificate of analysis.  
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1.4.2.2 Dexamethasone (DEX)  
While the cyclic structure of Rapamycin causes it to remain in the body for a long time, the 
structure of Dexamethasone (DEX) shown in Figure 3 allows it to leave the body relatively fast. 
The biological half-life of Rapamycin is 57-63 hours compared to DEX, which is excreted from 
the body in approximately 190 minutes. [31] [32] There are other differences in these two 
immunosuppressant drugs including suppressant mechanism and water solubility. Dexamethasone 
is a corticosteroid and is soluble in water. [33] It can be encapsulated in nanoparticles and aid 
scaffolds in a similar fashion as Rapamycin. The mechanism of anti-inflammatory action of 
dexamethasone [34] 
 
 
Figure 3.Skeletal formula of dexamethasone by Ed (Edgar181) - Own work, Public Domain. 
 
 
1.5 Purpose of Experimental Procedures and Aims 
The purpose of this study is to develop a drug delivery system that imposes minimum immune 
response. A three-component system will be used for this purpose, bringing together tissue 
engineering scaffold, nanoparticle, and immunosuppressant drug. This system should be easily 
customizable so that it may find use in the pursuit of others. MA alginate scaffolds will be used 
due to their heavily tunable mechanical properties and biocompatibility. Moreover, they can be 
tailored to have high enough elastic properties to be injected via conventional needle and retake 
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shape after extreme compression, leading to minimum immune reaction from less invasive 
introduction. PLGA nanoparticle with and without immunosuppressant drug will also be 
embedded into MA alginate scaffolds. These particles immune response must also be investigated 
and potentially minimized using PEG copolymerization, RBCM cloaking, and drug delivery. This 
drug delivery must be at ease of fabrication of both hydrophobic and hydrophilic drugs, high 
encapsulation efficiencies, and controlled/sustained release.  
To summarize, the specific aims of this study are: 
1) To develop a drug delivery system that solicits minimum immune reaction and can be 
easily incorporated/customized.  
2) Study the effects of cell recruitment based on nanoparticle surface and encapsulated 
characteristic.  
2. ABET Qualified Design Component 
2.1 Design Overview 
The purpose of this drug delivery system offers many design constraints. It must be easily 
incorporated into the research of others meaning it must be highly customizable, able to 
encapsulate a range of drugs (amphiphilicity), and have ease of fabrication. Its applications will 
be over a range of tissue engineering approaches, regenerative medicines, and immunotherapies 
meaning it must be biocompatible and elicit minimum immune response. To accommodate these 
constraints MA alginate embedded with nanoparticles, which encapsulate drugs is proposed. Each 
component of the system is highly customizable. The MA alginate can vary in mechanical 
properties, pore size, network distribution, and can be further customized by adding functional 
links/groups. The design of the alginate scaffolds will control how cells interact with the scaffold. 
Large pore size will give cells the ability to migrate into and out of scaffolds; and interconnected 
pore structure will allow for enhanced growth through nutrient transfer (possible vascularization). 
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The nanoparticles can vary in composition, size, distribution, and functional/targeting group. The 
nanoparticle design can minimize its immune response, allowing for longer circulation of the 
nanoparticle without phagocytic ingestion. Moreover, the drug encapsulated can be hydrophobic 
or hydrophilic depending on particle synthesis method, allowing for the encapsulation of proteins, 
cytokines, gene therapies, etc. The nanoparticle composition in conjunction with the drug 
interaction will determine its release profile.  
 
Biological inertness was the main focused variable, tailoring all components to attempt to 
minimize immune response. To minimize immune response alginate (a natural biocompatible) 
polymer was chosen and formulated into a gel through methacrylation instead of ionic crosslinking 
which causes ion transfer in the body. Nanoparticles were synthesized from PLGA and copolymers 
(biocompatible) with surface modifications including PEGylating and RBCM coatings, which 
have shown cloaking abilities. Lastly immunosuppressant drugs were encapsulated in PLGA to 
further subside the immune response through steady release. To show encapsulation range, a 
hydrophobic and a hydrophilic immunosuppressant drug was loading into PLGA nanoparticles.   
 
2.2 Design Comparison and Analysis 
In order to best analyze and compare the design components, a SWOT diagram, a decision matrix, 
and a system block diagram were used. These design aids clearly illustrate the advantages and 
disadvantages of each specification of the potential designs, and help to optimize an 
immunologically minimized drug delivery system.  
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2.2.1 SWOT Analysis 
SWOT (Strength-Weakness-Opportunity-Threat) analysis was performed on the 3-component 
drug delivery system, as shown in table 1. The strength of this system is that it provides a means 
to delivery drugs in a 3-dimensional scaffold. If nanoparticles were injected directly into the patient 
there would be no anchor to force localized drug delivery, as they would be transported away. In 
scaffolds the nanoparticle have an environment to release drugs and stimulate tissue growth, 
healing, or immunotherapy. These opportunities are further increased by the highly customizable 
nature of the materials selected. Scaffolds can range in mechanical properties, promoting specific 
cell differentiation or cell recruitment and modulation for tissue engineering and therapeutic 
approaches respectively. The potential weakness to this system is the drug delivery control. If the 
system is altered in such a way that scaffolds do not maintain integrity then nanoparticle may 
diffuse out, which may be a potential benefit depending on application. Nanoparticle formulation 
alterations could pose a burst release threat, which once again is only a threat due to the desired 
sustained release, but could be a benefit depending on application. To summarize this system has 
the advantage of offering a highly customizable local drug delivery system with minimum immune 
response but has the disadvantage of balancing formulation parameters to control the release 
profile.  This analysis provides for additional design constraints which can limit the potential 
weakness and threats, which are coupled. To reduce the threat of burst release, formulate the 
nanoparticles for sustained release and to reduce the threat of nanoparticle release from scaffold 
formulate the scaffold to a minimum stability modulus. This design is not trivial and each 
component can affect the other. For instance, the ratio of nanoparticles embedded to scaffold 
volume will affect the mechanical properties of the scaffold.   
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Table 1. SWOT analysis of Drug Encapsulated Nanoparticle Embedded Scaffold Design. 
 
Helpful Harmful 
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l 
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Strengths 
Allow for localized and controlled 
delivery of therapeutic drug 
molecules with minimum immune 
response.  
Weaknesses 
Limits the dose to the encapsulation 
of the nanoparticles and the number 
of nanoparticles loaded in a scaffold.  
 
Opportunities: 
Highly customizable allowing for the 
use in tissue engineering, 
regenerative medicine, and 
immunotherapies.  
Threats:  
Possibility of burst release 
depending on nanoparticle 
formulation and scaffold integrity.  
 
2.3 Decision Matrix 
A decision matrix was used to formally compare the design components of the drug delivery 
system. Scores were assigned on a 1 to 5 scale depending on ease of fabrication/functionalization 
and incorporation, with 5 being the most ease. The scaffold design will be held constant while the 
nanoparticle design will be augmented to investigate immune response. The decision matrix helps 
guide a relative ranking of the potential success of varying the nanoparticle design based off a 
specific criterion. This criterion includes the ability for the nanoparticle to be functionalized or to 
what extent its surface has been functionalized, the ability to control the size of said particle, its 
encapsulation efficiency or to what extent it can hold another molecule (drug), its ability to be 
embedded in scaffold, its ease of fabrication, and its potential immune response. Blank PLGA, 
PEGylated PLGA, RBCM coated PLGA, and DEX encapsulated PLGA nanoparticles were 
compared, as shown in table 2.  Some of the design criterion are coupled and affect the others 
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score. For instance, PLGA in a single solvent synthesis process will heavily agglomerate limiting 
its size manipulation earning it a score of 1, which is undesirable. While encapsulation of DEX 
requires the use of another solvent which increases its size manipulation score to 2. PEGylation 
further reduces agglomeration increasing the size manipulation score to 4. Each score was made 
considering the effects of secondary contributions as described. The scores were added and ranks 
were given. From the scores, PEGylation, RBCM coating, DEX encapsulation, followed by blank 
PLGA nanoparticles are the order of design ranking.  
 
Table 2. Decision Matrix of delivery NP component design. 
 
 
2.4 Systems Block Diagram 
To better understand the mechanism of immune response minimization the system block diagram 
in figure 4 is shown below.  The nanoparticles embedded in the scaffolds will not only be anchored 
Options 
PLGA embedded 
NP (Blank) 
PLGA: PLGA-
PEG embedded 
NP (Blank) 
RBCM coated 
PLGA embedded 
NP 
PLGA 
embedded NP 
with DEX 
encapsulated  Criteria 
Functional 
augmentation 
1 4 5 2 
Size manipulation 1 4 2 2 
Encapsulation 
efficiency 
3 4 3 3 
Embedding efficiency 5 5 5 5 
Ease of fabrication 5 3 1 3 
Potential immune 
response 
1 4 5 3 
Score 16 24 21 18 
Rank 4 1 2 3 
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in location by the scaffolds, but will also provide immune shielding capabilities to the scaffolds. 
This will be specific to the nanoparticle embedded. Dexamethasone, an immunosuppressant drug 
was loaded into PLGA nanoparticles to reduce the immune response. This was compared the 
PEGylation and RBCM coating surface modifications. Both act to limit nonspecific protein to 
surface binding. Moreover, it would be interesting to see if the composition of the nanoparticle 
embedded in scaffold could recruit different cells to the scaffold. If specific immunological 
reaction can be controlled, many more potential immunotherapies could find successes. For 
instance, the ability to recruit dendritic cells could open the possibility of tolerogenic 
immunotherapies finding success.   
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2.5 Design Criteria 
In order to construct the nanoparticles, which would be embedded into scaffolds, several design 
parameters were fixed. The criterial and rational are as follows: 
Particle size: The nanoparticles had to adhere to under 300 nm and be within 70 nm of one another 
in diameter. Particles of this size can be easily ingested through phagocytosis by dendric cells and 
macrophages, which are 10-15 μm. The nanoparticle size may also alter the elastic modulus of the 
gel, making it stiffer in large enough sizes and/or concentrations.  
 
 
Figure 4. Design Block of nanoparticle immune response minimization. 
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Particle synthesis: A double emulsion synthesis was employed for all the particles to ensure that 
both hydrophobic and hydrophilic molecules could be loaded. Also, the use of cytotoxic chemicals 
such as PVA were excluded, creating the need for another particle dispersive mechanism.  
Scaffold: MA alginate scaffolds with consistent pore size of 60 nm and interconnected pores were 
fabricated to hold the nanoparticles. These scaffolds have tunable mechanical properties and can 
easily be tailored to fit the application.  
Cytokine Selection: The target markers to track were from dendritic cells and T-cells. From many 
lymphocytes, this pair has shown the ability to present antigens and relay tolerance. CD11 is a 
marker expressed by both dendritic cells and macrophages, while the expression of F480- can be 
attributed to just dendritic cells. By this method, they will be tracked to see if specific immunity 
can be achieved. Other markers including PD-L1, MHC-11, and CD11b will be used further 
describe the state of dendritic cells (antigen presenting, mature, etc.).   
3. Materials and Methods 
3.1 Nanoparticle Synthesis  
Dichloromethane, chloroform, and acetone were purchased from Fisher Scientific and used 
without purification. Instruments used for nanoparticle synthesis include Eppendorf A6 centrifuge 
5424, Fisher Scientific Probe (500 watts, 200kHz0 and Bath (FS30D) sonicators. For 
encapsulation and release studies Rapamycin was purchased from LC Laboratories (R-5000, M.W. 
914.17 g/mol); and Dexamethasone was purchased from Sigma Aldrich (D9184, M.W 392.46 
g/mol). DiD was purchased from Molecular Probes (manufacturer: Life Technologies). Scaffolds 
were formulated from methacrylated sterile sodium alginate (2% H2O) purchased from 
NovaMatrix (manufacturer: OctoPlus NV, Netherlands).  
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3.1.1 PLGA Blank  
PLGA nanoparticles were synthesized without the use of PVA. Briefly, 50: 50 Poly(DL-lactide-
co-glycolide) with inherent viscosity of 0.66 dL/g was purchased from Durect Co. (Birmingham 
Division, USA), initiated with glycolic acid. PLGA was dissolved in dichloromethane to a 
concentration of 10 mg/mL and added in a 20:1 ratio to 25 μL tris(hydroxymethyl)aminomethane 
(Tris) Buffer at normal concentration (pH=8, HCl adjusted). This solution was oil in water 
emulsified using probe sonication (30% amplitude, 1 min, pulse: 2 seconds on and 1 second off) 
in a bed of ice. Additional Tris buffer at 10 mM concentration was added to this solution in the 
amount of 5 mL and sonicated again to form a double emulsion (DE) containing an aqueous inner 
phase. This DE solution was added dropwise to 10 mL of 10 mM Tris buffer and stirred overnight 
to allow solvent evaporation, at atmospheric pressure. Particles were collected by centrifugation 
at 4000 rcf and washed in 10 mM Tris buffer.  
3.1.2 PLGA: PLGA-PEG, PLGA: PLA-PEG 
Copolymer’s were added in a series of ratios to determine if size could be controlled through 
composition. PLGA-PEG was purchased from Polyscitech in a mPEG-PLGA ratio of 5,000: 
20,000 Da. PLGA-PEG was dissolved in DCM in a matching concentration to PLGA and added 
in specific volume ratios (PLGA: PEG, 5:1, 2:1, 1:1, 1:0). For the in vivo study a 2:1 PLGA: 
PLGA-PEG ratio was used. Briefly, 333 μL of PLGA was mixed with 167 μL of PLGA-PEG both 
in DCM at a concentration of 10 mg/mL to create the polymer phase. The same procedure outlined 
above was enlisted after this initial augmentation. PLGA: PLA-PEG nanoparticles were also 
synthesized in similar fashion simply substitution PLGA-PEG with PLA-PEG.  
3.1.3 RBCM PLGA 
Blood was harvested from B6 mice to collect the Red Blood Cell Membrane (RBCM). Blood was 
washed in Ethylenediaminetetraacetic acid (EDTA) buffer 3 times. In each wash cycle EDTA and 
26 
 
10x PBS were added to the RBCM and centrifuged at 18,000 rcf for 6 minutes. The supernatant 
was removed for the next cycle. This solution was then probe sonicated in a bed of ice for 2 seconds 
at 20% amplitude. RBCM and PLGA nanoparticles were directly combined in a 1: 1 volume ratio 
and bath sonicated for 10 minutes.   
3.1.4 PLGA, PLGA-PEG with DEX, RAPA, DiD loaded  
Dexamethasone was encapsulated in PLGA for the in vivo study. Rapamycin (RAPA) was also 
loaded in PLGA and copolymers to study its release. To load DEX in PLGA the same procedure 
to synthesis the blank particles was invoked with the addition of 100 μL of 5 mg/mL DEX 
dissolved in acetone added in the first emulsion. To load RAPA, which is hydrophobic, a single 
emulsion procedure was used. Briefly, PLGA and PLGA-PEG were both dissolved in chloroform 
at a concentration of 66 mg/mL and added together with a copolymer ratio ranging between 0 and 
50%. RAPA in a concentration of 1.33 mg/mL dissolved in chloroform was added to this solution 
(a high concentration RAPA was also investigated at 13.3 mg/mL). 100 μL of the polymer solution 
mixed with 100 μL of the drug and 0.8 mL of 5% PVA solution was probe sonicated in an ice bath 
to create a single emulsion. The single emulsion was extracted in 5 mL of 0.1% PVA solution and 
the solvent was stir evaporated overnight, at atmospheric pressure. Particles were collected and 
washed in water by centrifugation at 2000 rcf for 5 min. Lastly, to image nanoparticles in scaffolds 
DiD was loaded into PLGA particles following the previously described procedure adding 5 μL of 
0.1% DiD to the first emulsion.  
3.2 Fabrication of MA alginate Scaffolds 
2% MA alginate was used to fabricate scaffold in a Cryopolymerization process utilizing a 
biological safety cabinet for the in vivo study. Embedded nanoparticles were washed in filtered 
Tris Buffer (10 mM) with almost all the supernatant removed when complete. 1 mg of nanoparticle 
solution in 50 μL of Tris buffer was mixed in a 1: 1 volume ratio with MA alginate solution. This 
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solution was vortexed for 10 seconds before Granulocyte-macrophage colony-stimulating factor 
(GM-CSF) was added at 0.1 mg/mL and the solution was vortexed again. TEMED and APS (at 
100 mg/mL in H2O) initiators were used to cross link the scaffold. TEMED was added first at a 
ratio of 0.64 μL initiator to 100 μL scaffold solution and APS was added at a ratio of 2.5 μL per 
scaffold. Scaffold solutions were placed in syringes to acquire their shapes and placed in a freezer 
at -20 C. At this temperature, the water that freezes in the scaffolds with provide the obstacle to 
polymer solution to form interconnected pores.  Scaffolds to be imaged were fluorescently labeled 
with the addition of 1 μL of 10 mg/mL FITC-BSA in the initial alginate solution. Nanoparticles to 
be imaged in scaffolds were loaded with DiD, as described in section 3.1.4, and embedded into 
scaffolds following the outlined procedure above.  
3.3 Characterization of Nanoparticles and scaffolds (DLS, SEM, TEM, and confocal) 
Nanoparticle size was determined with Zetasizer Nano ZS (Malvern Instruments, UK). Particles 
were suspended in either water, PBS, or Tris buffer in dilute concentrations and size and 
distribution data was collected in 12 reading averages. SEM was used to determine nanoparticle 
shape by lyophilizing, spray coating, and then imaging the particles. TEM was used to confirm 
RBCM coating by the following sample preparation procedure: A carbon film coated Cu grid was 
cleaned with plasma, and 10 μL of nanoparticles with a concentration of 0.2 mg/mL were added 
on the grid; after 30 min, the grid was washed with ddH2O; 5 μL of 2% uranyl acetate water 
solution was added to the grid and filter paper was used to instantly absorb solution (3 times); 
samples were left to air dry. The prepared samples were imaged with a JEOL JEM2100 
transmission electron microscope (200kV operating voltage). Confocal microscopy was used to 
image scaffolds by adding either FITC-BSA to scaffolds or DiD markers to nanoparticles for 
encapsulation.  
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3.4 Release Studies 
3.4.1 Rapamycin release 
The release of rapamycin from different ratios of PLGA: PLGA-PEG (5:1, 2:1, 1:1, 1:0) was 
studied. Nanoparticles were suspended in a fixed volume of PBS and placed on a shake rack. Daily, 
nanoparticles were spun down at 2000 rcf for 5 min, the supernatant was collected, and the fixed 
volume of PBS refilled. Each time pull required the collection of three samples for statistical 
relevance. Release profiles were created for the first week of drug release. Rapamycin 
concentration was measured in each sample by absorption reader (TECAN Infinite 200) (signal 
peak at 278 nm). RAPA release from PLGA: PLA-PEG particles was also tracked in similar 
fashion. The encapsulation efficiency of RAPA was also calculated by dissolving nanoparticles in 
acetone nitrile and measuring the concentration signal.   
3.4.2 Dexamethasone release 
As the immunosuppressant drug of interest, DEX release was studied from PLGA particles. As 
these particles tend to agglomerate easily in water and PBS, 10 mM Tris buffer was used to track 
the release. In a similar procedure described above, nanoparticles were suspended in a fixed 
volume of Tris buffer and placed on a shake rack. Daily, nanoparticles were spun down at 4000 
rcf for 5 min, the supernatant was collected, and the fixed volume of Tris buffer was refilled. 
Release profiles were once again created for the first week of DEX release by measuring the 
concentration of DEX in each sample (3 for error bar) using TECAN (signal at 248 nm). The 
encapsulation efficiency of DEX was also calculated by dissolving nanoparticles in acetone nitrile 
and measuring the concentration signal, the signal peak shifted to 258 nm. 
3.5 In vivo Study  
3.5.1 Cell counting 
An in vivo study was performed using 4 B6 mice. The nanoparticles of interest were embedded 
into scaffolds making one control and 3 experimental conditions which are as follows: PLGA 
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Blank scaffold, PEGylated PLGA scaffold, RBCM coated PLGA scaffold, and DEX encapsulated 
PLGA scaffold. 2 of each scaffold was injected subcutaneously into the left and right backsides of 
the mice, dedicating one mouse per scaffold condition.  Scaffolds were kept in mice for 4 days 
before mice were sacrificed and scaffolds were collected. Upon collection scaffolds were initial 
broken up with mechanical force using pipettes. Afterwards, 1 mL of collagenase 2 was added per 
sample and samples were placed on shake rakes for 40 minutes. Samples were then filtered with 
cell strainers (70-micron mesh size) using PBS. Cells were collected by centrifugation at 15,00 
RPM for 5 minutes for cell counting.  
3.5.2 Flow Cytometry 
Cells were identified via flow cytometry (BD FACSCanto). For each condition, 0.25 million cells 
were collected by centrifugation at 400 rcf for 5 min. Non-specific binding signal was blocked 
with the addition of anti-CD16/32. Cells were then stained to track leukocytes, specifically T-cells 
and dendritic cells. For DC, CD11c was stained. In addition, F4/80 was stained to differentiate 
between DC and macrophages, MHC-II to determine antigen presenting abilities, PDL-1 to 
determine tolerogenic characteristic, and CD86 to determine maturity. For T-cells, CD3, CD4 and 
CD8 were stained and their markers tracked.  
4. Results and Discussion  
4.1 Nanoparticle Characterization 
4.1.1 Particle size, PDI, and Shape 
4.1.1.1 PLGA: PLGA-PEG 
The particle size, as characterized from DLS is shown below in Table 3 for the PLGA: PLGA-
PEG particles. It can be seen that the overall effect of PEGylation, at the extremes, is a decrease 
in particle size. The lowest particle size is obtained when 50% PEGylation occurs at a 1 to 1 ratio. 
PLGA particles have the largest particle size of 719.2 nm (chloroform solvent). These particle, 
were made using PVA but still this size is increased by agglomeration of particles, whereas the 
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PEGylated PLGA is less likely to agglomerate due to the PEG side chain. Reducing PEGylation 
also helps to form the spherical shape of nanoparticles, as revealed by SEM images below.  
 
Table 3. PLGA: PLGA-PEG Particle size by ratio, characterized by DLS. 
Ratio PLGA to PLGA-PEG PLGA-PEG (%) Size (nm) PDI 
1 to 0 0.00% 719.2 0.03 
5 to 1 16.67% 604.5 0.303 
2 to 1 33.33% 645.2 0.114 
1 to 1 50.00% 558.2 0.104 
 
 
Scanning Electron Microscopy images of PLGA: PLGA-PEG nanoparticles are shown in Figure 
5. Selection the ratios at the extremes (5: 1 and 1: 1) it is clearly seen that spherical particle 
formation is facilitated by the reducing of PEG. Since PEG chains are hydrophilic, they can affect 
the double emulsion process. A different mechanism must be used to prevent agglomeration if 
particles are to be coated as PEGylation prevents coatings.   
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Figure 5. SEM images of PLGA: PLGA-PEG 1:1 left, 5:1 right. 
 
4.1.1.2 PLGA: PLA-PEG 
To compare, another copolymer PLGA: PLA-PEG nanoparticles were synthesized (DCM used as 
solvent) in matching ratios of PLGA: PLGA-PEG as shown in Table 4. This result differs greatly 
from the last one. With the copolymer composition changed to PLA-PEG, increasing the 
PEGylation led to larger particle sizes from the control, as seen by table 4. However, this increase 
was at low concentrations of PEG, increasing PEG eventually led to little to no effect on particle 
size. Due to the highly customizable criteria of our system, PLA-PEG is not desirable as a 
copolymer because the size cannot be easily changed with copolymer ratio. Comparing this result 
to the last one, it was noticed that PLGA dissolved in DCM resulted in smaller particle size than 
it would if dissolved in chloroform (see Tables 3 and 4 row 1). The use of a more volatile solvent 
led to a 38.4% reduction in particle size among the PLGA control particles using the same 
synthesis conditions.   
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Table 4. PLGA: PLA-PEG particle size by ratio, characterized by DLS. 
Ratio PLGA to PLA-PEG PLA-PEG (%) Size (nm) PDI 
1 to 0 0.00% 443.3 0.245 
5 to 1 16.67% 972.2 1.00 
2 to 1 33.33% 533.6 0.057 
1 to 1 50.00% 552.3 0.153 
 
4.1.1.3 RBCM 
To synthesis RBCM coated PLGA two major obstacles had to be overcome: 1. Agglomeration and 
2. Size fitting. The first obstacle arises because PVA nor PEG can be used as deagglomerating 
agents when RBCM coating is desired. The second obstacle refers to the need for the RBCM 
vesical to match the size of the PLGA nanoparticles it is coating. The first obstacle was solved 
using charged solution (Tris Buffer), which could cause the solute nanoparticles surface to have a 
slight charge and electrostatically repel one another leading to deagglomeration. Particle size 
confirmed that deagglomeration occurred as it was much lower than particle size information 
gathered from agglomerated particles (~69% reduction in size). The second obstacle was solved 
by varying the sonication time the RBCM vesical was subjected to, resulting in a procedure that 
matched the sizes of the deagglomerated PLGA particles. Table 5 shows a comparison of the 
PLGA to RBCM vesical sizes. It can be seen, that the RBCM vesical is only 7.4 nm larger than 
the PLGA particles. This size match facilitates RBCM coating PLGA particles.  
 
 
33 
 
Table 5. PLGA and RBCM particle size comparison, characterized by DLS. 
 Size (nm) PDI 
PLGA NP 222.5 0.095 
RBCM vesicle 229.9 0.209 
 
Transmission Electron Microscopy was used to confirm RBCM coating as seen in Figure 6. On 
the left PLGA nanoparticles can be seen matching the size obtained from DLS. On the right the 
same particles appear to be enveloped in RBCM vesicles. These vesicles now are in position to 
cloak the PLGA particles.  
 
 
 
 
 
4.1.1.4 In vivo Study 
PLGA Blank, PLGA: PLGA-PEG (2: 1), DEX loaded PLGA, and RBCM coated PLGA 
nanoparticles were embedded in scaffolds and studied in vivo. For accurate comparison, the 
100 nm  100 nm  
Figure 6. TEM image of a) PLGA NP and b) RBCM coated PLGA NP 
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particle size of each particle had to remain within 100 nm of one another as to not alter the 
mechanical characteristics of the scaffold and bias the results. To ensure phagocytosis was 
possible, nanoparticles were restricted to under 300 nm in diameter. These additional two design 
criteria were met, as seen in Table 6.    
  
Table 6. Nanoparticle for in vivo study size comparison, characterized by DLS. 
Nanoparticle Size (nm) PDI 
PLGA Blank 223.5 0.031 
PLGA-PEG 293.5 0.129 
PLGA w/ DEX 239.4 0.059 
RBCM Coated  293.9 0.0172 
 
4.1.2 Release Profiles  
4.1.2.1 Rapamycin 
The cumulative percent release of rapamycin from PLGA with different ratios of PLGA-PEG are 
shown in Figure 9. The PLGA without PLGA-PEG releases the most RAPA, among all the 
samples, in the time given. The addition of PLGA-PEG causes a noticeable shift in the release 
profile regardless of concentration, to lower release rates and less initial burst release. In one week, 
the PLGA nanoparticles released 60% of the encapsulated RAPA while the addition of 16% 
PLGA-PEG led to a release of 31%. That is a decreased release rate by a factor of 2. By increasing 
the amount of PLGA-PEG to 33%, a cumulative release of 36% was obtained; and for 50% PLGA-
PEG, a cumulative release rate of 40% was observed.  
The addition of a small amount of PLGA-PEG led to a release rate reduction by half, but the 
increased addition of PLGA-PEG seems to have diminishing returns. By doubling your initial 
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PLGA-PEG concentration the release rate is only slowed by an additional 5% and by again tripling 
your initial addition of PLGA-PEG, the release rate is only slowed by an additional 9%. The system 
is not sensitive to compositional changes after the initial surface modification. PEGylation will not 
affect release rate in certain composition ranges, yet can be used to tune particle size. This makes 
PEGylation an ideal candidate for a customizable 3-component nanoparticle embedded scaffold 
with minimizable immune response.  
 
 
The encapsulation efficiency of PLGA: PLGA-PEG nanoparticles are shown in Table 7. The 
PEGylation of PLGA nanoparticles has no statistical effect on the encapsulation efficiency (EE) 
of the particles. 
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Figure 7. RAPA Release Profile from PLGA: PLGA-PEG. 
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Table 7. PLGA: PLGA-PEG NP Encapsulation Efficiency of RAPA. 
Percent PLGA-PEG Encapsulation Efficiency (%) 
0.00% 21.24% 
16.67% 23.26% 
33.33% 19.95% 
50.00% 22.98% 
 
By changing the composition of copolymer to PLA-PEG, the percent of PEGylation displays an 
effect on encapsulation efficiency, as seen in Table 8. The first row of Tables 6 and 7 shows that 
the use of DCM increases the EE by a factor of 3 from roughly 20 to 60%. The addition of 16.67% 
PLA-PEG to PLGA decreases EE and the trend continues with more PEGylation leading to less 
EE, in a nonlinear fashion. Due to the affect PLA PEGylation has on PLGA EE, it was not used in 
the in vivo experiment. RAPA was not used in the in vivo study either, as immunosuppressant 
mechanism is much harder to control compared to DEX. Its successful encapsulation and release 
profile provide insight on the encapsulation of a hydrophobic drug.  
 
Table 8. PLGA: PLA-PEG NP Encapsulation Efficiency of RAPA. 
Percent PLA-PEG Encapsulation Efficiency (%) 
0.00% 60.26% 
16.67% 57.35% 
33.33% 38.90% 
50.00% 32.53% 
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4.1.2.2 Dexamethasone 
The release of DEX from PLGA nanoparticles was also investigated as shown in Figure 8. 
Cumulative release rates of DEX and RAPA from PLGA nanoparticles can be compared by 
looking at both blue lines of Figures 10 and 9, respectively. In 7 days, the roughly 60% of the 
encapsulated RAPA was released while on about 55% of the DEX was released in that time (60% 
was released in 8 days). The major difference in the release profile of DEX is the lack of an extreme 
initial burst release. Almost 30% of the RAPA was released in the first hour compared to only 10% 
of the DEX. By the first day 40% of the RAPA had been released and this release rate dramatically 
changes as it takes the next 6 days for an additional 20% RAPA to be released. This is in contrast 
with the DEX release, which after the first day displays a steady release rate of about 5.5% DEX 
initially encapsulated per day.  
 
Figure 8. Cumulative Release of DEX from PLGA NP. 
 
0%
10%
20%
30%
40%
50%
60%
70%
0 1 2 3 4 5 6 7 8 9
P
er
ce
n
t 
R
el
ea
se
Time (day)
DEX Cumulative Release from PLGA NP
38 
 
These difference in release rates can be attributed to the solubility characteristic of each drug and 
mainly the particle synthesis method. Rapamycin is hydrophobic, allowing it to more easily diffuse 
through the polymer nanoparticle. While dexamethasone is more hydrophilic and would rather 
remain inside the internal aqueous environment created by the double emulsion process. On the 
other hand, the single emulsion process used to synthesize RAPA loaded nanoparticles provides 
less obstacles for diffusion of the drug seen by the burst initial release driven by the initial high 
concentration gradient; which levels off. In contrast to layer diffusion process, which is determined 
by time which explains the steady release of DEX synthesized from the double emulsion process. 
Double emulsion is thus more desirable nanoparticle synthesis route for this system.  
 
4.2 Scaffold Characterization  
Confocal microscopy was used to image FITC-BSA labeled MA alginate scaffolds as shown in 
Figure 9. This image shows that the surface of the scaffold has smaller pore structure than its 
center, as shown by the large pore size of the cut scaffold. Cells are of the size order of 10 microns, 
meaning that these scaffolds with an average surface pore size of 60 microns can accommodate 
the migration of cells.  
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Figure 9. Alginate scaffold imaged by confocal microscopy. Surface of scaffold shown on left, cross-section on the right. 
 
 
To verify that nanoparticles were embedded in walls and not simply collected in pores, in which 
they could leak out and not retain localized properties, nanoparticles where given fluorescent 
character and imaged in scaffolds. DiD was encapsulated in PLGA nanoparticles which were 
imbedded in non-fluorescent scaffolds. Therefore, the only imaging signal must emanate from the 
nanoparticles and their location can be identified. Confocal microscopy images of these scaffolds 
are shown in Figure 10. At a low image magnification of 10X the pores of the scaffolds appear 
visible and resemble the scaffold imaged in Figure 9. However, at higher magnifications the walls 
of the scaffold appear speckled; and at a magnification of 60X it is apparent that the nanoparticles 
emitting the fluorescent signal are embedded in the scaffold walls. Nanoparticles appear to 
contribute a large percent to the volume of the scaffold, which follows the 1 to 1 volume ratio 
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synthesis path.  The large number of nanoparticles constituting the scaffold could possible imbue 
their immune characteristics to the scaffold.  
 
 
Figure 10. Confocal microscopy of DiD labeled PLGA NP embedded in Alginate Scaffolds. 
 
4.3 In vivo Experiment  
4.3.1 Dendritic Cells 
In vivo experiments were performed on B6 mice and cell counting and flow cytometry were used 
to collect information regarding the number and population of cells recruited to scaffolds. Figure 
11 shows the number of cells recruited to each scaffold. Each condition lowered the number of 
cells recruited to scaffolds. As expected the immunosuppressant drug release decreased the 
immune response to the largest extent. However, its result is like the decrease shown using 
PEGylation and RBCM coating.  
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Figure11. Total number of cells recruited to each scaffold. 
 
These cells can be identified by surface marker as shown in Figure 12. CD11c is a surface marker 
of dendritic cells. F4/80+ expression has been well characterized as a macrophage marker. While, 
Ly6G+ expression has been linked to the presence of neutrophils. The RBCM coated and DEX 
loaded PLGA nanoparticle scaffolds displayed the highest percent of cells expressing CD11c+ and 
F4/80+; and the lowest Ly6G+ expression. This means that with the help of GM-CSF, immune 
cells were recruited but specific cells were recruited depending on nanoparticle characteristic. 
Tracking the expression of Ly6G+, the percentage of neutrophil inflammation in order from highest 
to lowest, found in scaffolds are as follows: PEGylated scaffolds, PLGA blank scaffolds, RBCM 
coated scaffolds, and DEX loaded scaffolds. As a percentage of the total cells recruited, the 
PEGylated modified NP scaffold displayed a larger percent of Ly6G+ cells compared to the 
control, while other modifications displayed a reduced Ly6G+ population.  
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Figure 12. General cell recruitment identification using total number of cells and percent of cells recruited. 
 
It is surprising that the PEGylation increased the percentage of Ly6G+ expression. But it was 
expected for the DEX to elicit the least Ly6G+ expression followed by the RBCM, as compared to 
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This will depend on what specific cells are recruited to which scaffold composition and by what 
mechanism. To explore immune tolerogenic capabilities the recruitment of dendritic cells was of 
interest. Figure 13 shows the percentage of DC recruited by each scaffold, as seen by the separation 
of the CD11+ expressing cells into F4/80+ cross expressing macrophages and F4/80- DC. The 
PEGylated PLGA recruits a similar percentage of DC as the PLGA Blank control scaffold. While 
the RBCM coated and DEX loaded scaffolds recruited a higher percentage of DC. The next 
question now becomes the tolerogenic ability of the DC recruited. Slightly more macrophages are 
recruited by PEGylated nanoparticles as compared to the control.  
 
Figure 13. Dendritic Cell Recruitment for each scaffold as percentage of total cells recruited. 
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the highest). The trend being to arise is that PEGylation has minimum to a slightly negative affect 
on antigen presenting DC. However, they do show an effect on the number of macrophages 
recruited. The antigen presenting macrophages recruited in order of lowest to highest cell 
percentage are as follows: PLGA Blank, PEGylated PLGA, RBCM coated PLGA, and DEX 
loaded PLGA.  
 
Figure 14. Antigen Presenting DC Recruitment for each scaffold condition as a percentage of total cells recruited. 
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NP scaffold and RBCM coated behaves like DEX loaded PLGA NP scaffolds. The latter group 
recruited more tolerogenic capacity cells as seen by PD-L1+ expression.  
 
Figure 15. Tolerogenic ability of cells recruited for each scaffold condition as a percentage of total cells recruited. 
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coated NP scaffold showed higher recruitment than the DEX loaded NP scaffolds. This is an 
interesting result as it indicates a method of recruiting immature dendritic cells in greater quantities 
than DEX with RBCM. Their combined cell recruitment would most likely show further 
immunosuppression insight. The cells described in this section are usually referred to as immature. 
 
Figure 16. Immunosuppressive cell recruitment for each NP scaffold condition as a percentage of total cell recruitment. 
 
The ideal cell recruited for tolerogenic purposes would be a dendritic cell with antigen presenting 
capabilities, which can prime T-cells, in an immunosuppressive manner. Cells with these 
properties are thought to express a combination of the markers described above. Figure 17 shows 
the percent of cells recruited from each scaffold that expresses CD11c+, F4/80-, MHC-11+, 
PDL1+, and CD86-. These targeted immune cells are the cluster in the middle of the figure. In 
agreement with the trend, the PEGylated NP scaffolds had slightly fewer targeted cells than the 
control scaffold, yet the percentages are within error.  
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Figure 17. Target immune cell Recruitment based on antigen presenting tolerogenic immunosuppressive characteristic, as a 
percentage of total cells recruited for each NP scaffold. 
  
The RBCM coated and DEX loaded NP scaffolds both showed a higher percentage of targeted cell 
recruitment, with the DEX loaded containing the most. These results are expected as each marker 
has been individually analyzed and the collection of these markers are indicative of the target 
immune cells for recruitment. Macrophages, although not the targeted cell, show a clear trend with 
each condition recruiting more tolerogenic macrophages than the control. In increasing order, 
PEGylated, RBCM coated, and then DEX loaded NP scaffolds showed the highest percentage of 
tolerogenic macrophage cells recruited. It is worth noting that combined, tolerogenic DC and 
macrophages only constitute ~7.64% of the total number of cells recruited. 
4.3.2 T-cells  
CD11b is one component of a complement receptor, which functions as a pattern recognition 
receptor. It is found on many leukocytes (Natural killer cells, macrophages, granulocytes, etc.) and 
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increased immune response resulting in adhesion, cellular activation, and possible phagocytosis or 
cell-mediated cytotoxicity. Cells expressing CD11b- are thus indicative of decreased immune 
response resulting from less surface interaction and used as a prime strategy for selecting T cells. 
Figure 18 shows the percentage of cells that express this marker divided into two categories. The 
first category are cells that also express CD3+ and CD4+.  CD3 is a T cell marker and CD4 is 
helper T-cells. These cells are not cytotoxic like natural killer cells and being naïve means they 
have not found a threat to signal to the body. PEGylated and Blank PLGA NP scaffolds have 
similar percentage of these cells while RBCM coated and DEX loaded PLGA NP scaffolds have 
higher percentages of these cells.  
The second category of cells are CD3+ andCD8+ expressing cells, which are cytotoxic T-cells. 
Each condition is within the error of the control, in this category except the DEX loaded NP 
scaffolds with show slightly higher percentages. These cells constitute a small percentage of the 
total number of cells recruited (highest 2.31% in DEX loaded NP scaffolds).  
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Figure 18. T cell Recruitment of each NP scaffold as a percentage of CD11b- cells recruited. 
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5. Summary 
A scaffold with embedded nanoparticles was synthesized for the delivery of hydrophobic and 
hydrophilic molecules. It was designed to be highly tunable from the scaffolds mechanical 
properties to the nanoparticle composition. The focus of this scaffold was to provide insight into 
the immune response depending on nanoparticle composition. A minimum immune response was 
desired with possible future applications in immunotherapies, specifically immunosuppressant 
therapies. Several nanoparticle synthesis techniques were explored before single emulsion was 
used to encapsulate rapamycin and double emulsion was used to encapsulate dexamethasone. The 
release rates of each drug were studied and tuned to minimize initial burst release for steady 
release. Many nanoparticle compositions were explored to determine the relationship between 
composition and size, encapsulation efficiency, and release rate. From this exploration, a 
procedure nanoparticle conditions were chosen for an in vivo study. PLGA with no encapsulated 
drug was compared to PEGylated PLGA, RBCM coated PLGA, and DEX loaded PLGA. The 
PEGylation is of interest due to its ability to decrease nonspecific binding and particle size, RBCM 
coated PLGA has the potential to cloak the particles minimizing immune response. Lastly, to prove 
encapsulation, release, and provide a benchmark of a desirable result DEX loaded PLGA particles 
were investigated. Each modified nanoparticle was synthesized to be of similar size and embedded 
into alginate scaffolds. Scaffolds were subcutaneously injected into mice, retrieved, and analyzed 
to provide cell recruitment information.   
6. Conclusions 
6.1 General conclusions  
After completion of nanoparticle fabrication, it can be concluded that the size, encapsulation 
efficiency, and release can be controlled by fabrication route and variables. The size of NP was 
controlled by fine tuning fabrication variables, for instance dilute polymer concentration, intense 
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emulsion, and solvent selection can be used to fabricate NP’s between 200 nm and 1 micron 
(monodispersed). By using either a single or double emulsion process NP’s were synthesized that 
could encapsulate either hydrophobic or hydrophilic molecules, respectively; and encapsulation 
efficiency was controlled by solvent use and polymer composition to drug affinity. Encapsulations 
ranged between 20% and 60% depending on polymer composition and solvent used. Release 
profiles of encapsulated molecules were strongly determined by drug water solubility. 
Hydrophobic loaded drug (RAPA) displayed a burst release while hydrophilic loaded drug (DEX) 
displayed a linear release consistent with PLGA degradation rate. Release profiles were only 
slightly changed by PEGylation, while fabrication variables and polymer composition 
significantly changed release. Lastly from the in vivo study, the immune response was shown to 
change based on the physicochemical surface characteristic of nanoparticles embedded in the walls 
of alginate scaffolds. Each modification (RBCM coating, PEGylation, and DEX release) of PLGA 
NP’s resulted in fewer cells recruited to scaffolds. The overall goal is modulation and not complete 
immune suppression. To this end, population analysis revealed that the RBCM coating and the 
DEX release NP modifications recruited fewer Ly6G+ cells while PEGylated NP recruited more 
of these cells as compared to the control. The same trend was seen in the recruitment of helper T 
cells. However, there was no significant difference in the CD3+CD8+ population. It is believed that 
through reduced protein binding these results were obtained. Extending from a reduced leukocyte 
infiltration into the inflammatory site from DEX immunosuppression mechanism and from the 
RBCM coating which, provides the CD47 “self” identifier to NP, as it is a ubiquitous 
transmembrane protein to all cells in the body.  The following is a summary of the conclusions 
reached: 
Nanoparticle: Size, release, and EE can be controlled through particle fabrication & composition.  
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Scaffolds: Immune response can be changed by controlling the biophysical chemistry of 
nanoparticles surfaces and encapsulation. Red Blood Cell Membrane (RBCM) coated PLGA 
and DEX release PLGA NP’s embedded scaffolds both reduced Ly6G+ population and 
increased the number of helper T-cells recruited to scaffolds.  
6.2 Specific Aims and Design Criteria 
The specific aims and design criterial were evaluated to conclude this study and provided any 
design relevance. Specific aims can be read in section 1.4. Briefly, they were to develop a drug 
delivery system that solicits minimum immune response and can be incorporated into many 
applications; study the immune effect of different nanoparticles embedded in scaffolds; and study 
the cell recruitment of each scaffold. The following are the conclusions that can be drawn with 
respect to each specific aim: 
1) Drug delivery system was developed that can either delivery hydrophobic or 
hydrophilic molecules using alginate scaffolds and augmented PLGA embedded 
nanoparticles. The alginate scaffold and nanoparticle synthesis and composition allow 
for many customizations and possible applications. With system control over particle 
size, shape, encapsulation, and release rate to characterized extents.  
2) Both surface modifications (PEGylation and RBCM coating) and DEX release led to 
a decreased immune response. Target immune cells were recruited to scaffolds in 
different amounts depending on embedded nanoparticle. Tolerogenic, antigen 
presenting, immature dendritic cells were recruited to scaffolds at varying amounts, 
providing avenues for optimization of current and potential immunosuppression 
therapies.  
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7. Recommendations 
7.1 Multiple drug encapsulation in single particle 
Due to the highly customizable nature of this system many recommendations seem appropriate for 
future investigation. The first would be the study of two different drug molecules encapsulated in 
nanoparticles. Using double emulsion polymerization one drug could be encapsulated in the inner 
aqueous phase while another is within the polymer casing. This additional drug could be an initial 
release or a primer for the next drug. Another possible route is the first drug is a burst release while 
the second is a steady release. This could be used to mimic basal/bolus drug delivery. Yet another 
possibility is the first drug is an immunosuppressant while the second is an antigen for tolerogenic 
adaption. This dual drug delivery could have many benefits, but one noticeable constraint is the 
need for one hydrophobic and one hydrophilic drug.   
7.2 Multiple type of Nanoparticle Loaded in Single Scaffold 
Another possible alteration is embedding two or multiple different types of nanoparticles in the 
same scaffold. Each nanoparticle could have a specific functional attachment or encapsulation. 
Nanoparticles could be randomly distributed or in specific sections of the scaffold. The 
nanoparticle placement could be achieved by allowing different nanoparticle-scaffold slurries 
Cryopolymerize in contact with one another, forming layers. Another method could be the 
inclusion of nanoparticles not only embedded in the walls but also distributed in the pores of 
scaffolds. The nanoparticles fixed in placed by the scaffold walls could provide localized delivery 
while the particles in the pores would disassociate, releasing nanoparticles in a larger area.  These 
methods could provide another dual encapsulation route as well as alternative treatment 
applications. It would be interesting to see the effects of RBCM coated and DEX release NP’s in 
the same scaffold. This combination could lead to further reduced foreign body immune response.  
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7.3 Characterization of Immune Cells  
The most promising facet of this system is the ability to recruit targeted immune cells. The ability 
to selectively gather and augment desired immune cells could open new treatments for many 
illness and specifically autoimmune diseases. This study focused on the nanoparticle composition 
and its effect on immune response. Nanoparticles from this study could be combined and studied. 
For instance, DEX could be loaded into RBCM coated PLGA, which could even further lower 
immune response. Another approach could be the use of cytokines encapsulated in nanoparticles 
embedded in scaffolds for specific cell recruitment. Also, functional groups could be used to 
further augment the surface and lead to specific cell recruitment or a different immune response.  
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